Legend Biotech Advances CAR-T Commercialization While Managing Operating Losses and Capital Expansion

Historical Performance

Legend Biotech's financial trajectory over recent years has been shaped predominantly by its strategic collaboration with Janssen focused on the BCMA-targeting CAR-T therapy CARVYKTI (cilta-cel). Since FDA approval of CARVYKTI in early 2022 for relapsed or refractory multiple myeloma (RRMM) patients, revenue has grown briskly as commercial sales ramped globally outside Greater China, where Legend acts as the principal seller.

Historical performance (annual)

Source: SEC companyfacts cache [F1].

Capital returns and efficiency (annual)

Source: SEC companyfacts cache [F1].

The jump in revenue between FY23 and FY24 reflects accelerating adoption and market penetration of CARVYKTI under Janssen's commercialization framework with Legend recognizing its share of collaboration net trade sales outside Greater China as collaboration revenue. Despite this acceleration, operating performance remains challenged by significant losses which narrowed from a peak net loss of over $500 million in FY23 to $296.8 million loss in FY25 [F1], signaling improving—but still negative—overall profitability.

Revenue Composition & Collaboration Model

CARVYKTI remains Legend's sole approved product contributing to revenue generation so far. The company's income streams break down into:

• Collaboration revenue from Janssen: pro-rata share of net trade sales outside Greater China where Janssen is principal.
• Product sales revenue from Greater China: Legend recognized as the principal here retaining or bearing roughly 70% of pre-tax profits/losses.
• License and milestone payments from other partners such as Novartis linked to ongoing development programs.

Under the December 2017 Janssen Agreement, both parties actively participate in development, manufacturing, and commercialization activities worldwide governed by global plans. Janssen conducts all clinical trials globally with participation from Legend's teams particularly focused on U.S. and Greater China regulatory dealings [S1]. This collaboration splits costs and pre-tax profits primarily on an equal basis except for Greater China’s different ratio.

Future Growth Prospects

Looking ahead, Legend anticipates continued investment into:

• Expanding indications for cilta-cel beyond current RRMM approvals.
• Manufacturing capacity-building including facilities located in the U.S., Europe, and China to meet both clinical trial supplies and commercial demand.
• Newly licensed products via agreements such as with Novartis targeting DLL-3 via LB2102 and other novel targets.
• Broadening clinical pipeline through R&D efforts for solid tumor programs and additional cell therapies.

Revenue growth will hinge on successful indication expansions for CARVYKTI along with commercialization execution primarily managed through Janssen globally but performed directly by Legend in Greater China. Equally important is advancement of their pipeline candidates progressing through clinical phases to eventual market launches [S1][S18].

Market exclusivity granted through existing FDA approvals supports near-term competitive positioning while ongoing IP protection fortifies barriers against entrants.

Forecasts & Milestones

Explicit company guidance or specific milestones were not provided in recent disclosures but areas to watch include:

• Progression of clinical trials for pipeline candidates—both internal and licensed—including timelines toward pivotal readouts.
• Expansion of regulatory approvals for cilta-cel into earlier lines of therapy or new patient populations.
• Scaling manufacturing output sufficient to satisfy growing demand without supply shortfalls.
• Realized milestones triggering license revenue under partnerships like Novartis [S15].

Investor focus should monitor quarterly collaboration revenues reflecting global sales dynamics alongside any updates regarding regulatory submissions or clinical data announcements that could materially affect timing or scale of product launches.

Returns & Capital Allocation

Legend Biotech does not currently generate positive returns on equity; FY25 saw a net loss of $296.8 million against equity base of roughly $1 billion yielding an approximate ROE near -29.6% [F1]. Operating cash flows improved but remained negative (-$100.2 million) indicating ongoing investment-heavy operations transitioning toward commercialization scale [F1][S10].

Significant capital expenditures (~$69 million in 2025) target manufacturing facilities refurbishment or construction primarily situated across U.S., Europe, and China [S15]. These investments are essential prerequisites for meeting complex supply chain and production quality demands inherent in cell therapy manufacturing compared to typical biologics production.

No dividends or share buybacks have been declared or discussed given the focus on preserving liquidity for operational investment and strategic growth initiatives [S6][S7].

Financial Position & Liquidity

The company maintained robust liquidity reserves entering 2026 with approximately $948.6 million comprising cash, equivalents, deposits plus investments supporting anticipated spending for at least the next twelve months [S1][F1]. While past losses accumulate near $2 billion since inception, equity financing rounds combined with upfront advances totaling several hundred million dollars from collaborations have fortified balance sheet strength historically [S12].

Obligations including lease commitments ($152 million total over next years) relative to capital commitments ($11.5 million) imply a manageable fixed cost structure given current scale [S5]. The next phase expansion will likely require continued equity or strategic financing backed by improving operational metrics around commercial uptake.

Industry Context & Strategic Positioning (Analysis)

CAR-T therapies have transformed hematologic oncology treatment paradigms but remain highly complex products with stringent manufacturing bottlenecks due to autologous cell sourcing requirements plus intricate quality controls. Legend’s partnership model with Janssen leverages complementary strengths—Janssen’s sales reach coupled with Legend’s proprietary technology platform—including critical process know-how embedded within the collaboration ensures scale economies while sharing risks mitigating solo commercialization burdens common among biotech peers.

Global cell therapy markets are expected to expand substantially driven by multiple pathway oncology indications plus nascent solid tumor applications where T-cell engineering faces higher hurdles but promises high unmet medical needs. Here Legend’s pipeline diversification targeting different antigens beyond BCMA positions it advantageously versus competitors more narrowly dependent on single assets or indications.

Risks & Considerations

Primary risks include:

• Regulatory uncertainties around expanded indications and regional approvals.
• Clinical trial outcomes that may delay or derail pipeline progression impacting future license payments.
• Heavy reliance on partner collaborations creates dependency vulnerabilities should terms change or strategic priorities shift.
• Continued operating losses necessitate sustainable capital access; unfavorable market conditions could impair financing availability or increase dilution risks.
• Manufacturing scale challenges inherent in complex cell therapies potentially limiting timely commercial supply.

Conclusion

Legend Biotech has progressed significantly post-CARVYKTI approval benefiting from robust collaboration structures underpinning its initial commercialization success reflected in more than doubling annual revenues between 2023–24 validated by proprietary CAR-T technology leadership. Nonetheless, ongoing operating deficits reflect investments necessary to broaden indications, scale manufacturing capability internationally, develop new candidates, and establish independent commercial presence especially within Greater China.

Financial resources appear adequate near term given sizeable cash reserves while stewardship decisions over capital expenditures and collaborative milestones will be pivotal to maintaining this runway during this inflection period where scientific promise meets operational execution risk.

This analysis summarizes publicly available data sourced mainly from the company’s recent SEC filings dated March 10, 2026 ([S1] to [S29]) complemented by financial facts ([F1]) without offering investment recommendations or price forecasts.

Disclaimer: This is research-only, informational analysis and not investment advice. It may include AI-generated interpretation and general industry context. Always verify important details using primary sources.